What is BioSkryb?
BioSkryb Genomics, based in Durham, North Carolina, is a venture-backed entity focused on pioneering genomic amplification technologies. The company's core innovation, the Primary Template-directed Amplification (PTA) system, addresses critical challenges in genetic analysis by enabling high-quality sequencing library generation from limiting samples. This technology is particularly valuable for applications requiring whole genome amplification, ultimately leading to more accurate and comprehensive genetic insights. The company's solutions are crucial for researchers and clinicians working with precious or scarce biological material.
How much funding has BioSkryb raised?
BioSkryb has raised a total of $11.5M across 1 funding round:
Angel/Seed
$11.5M
Angel/Seed (2020): $11.5M with participation from Wilson Sonsini Goodrich & Rosati and Anzu Partners
Key Investors in BioSkryb
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a prominent law firm established in 1961, specializing in corporate law, litigation, and intellectual property, providing essential legal counsel to technology and life sciences companies.
Anzu Partners
Anzu Partners is an investment firm dedicated to supporting breakthrough technologies in the life sciences and industrial sectors, offering strategic guidance and capital to accelerate the growth of innovative companies.
What's next for BioSkryb?
With a major enterprise-level funding context and a recent strategic investment, BioSkryb is well-positioned for scaling its operations and further developing its PTA technology. This capital infusion is likely to accelerate product development, expand market reach, and enhance its competitive standing in the genomics sector. The company's focus on reproducible, high-coverage amplification from low-input samples suggests a strategic move towards addressing unmet needs in advanced genetic sequencing, potentially impacting fields such as diagnostics, personalized medicine, and fundamental biological research. Future growth will likely involve broader adoption of its platform and continued innovation in amplification techniques.
See full BioSkryb company page
